查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006362

抗菌药物敏感性测试市场：按产品类型、测试类型、方法、应用和最终用户划分－2026-2032年全球市场预测

Antimicrobial Susceptibility Testing Market by Product Type, Test Type, Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗菌药物敏感性测试市场价值将达到 42.5 亿美元，到 2026 年将成长至 45 亿美元，到 2032 年将达到 64.3 亿美元，复合年增长率为 6.07%。

主要市场统计数据
基准年 2025 42.5亿美元
预计年份：2026年 45亿美元
预测年份 2032 64.3亿美元
复合年增长率 (%) 6.07%

简明策略概述，概述抗菌药物敏感性测试的趋势、营运挑战和诊断技术创新，以指导临床实践和研发 (R&D) 中的决策。

抗菌药物敏感性检测是临床微生物学和治疗管理的基础，影响全球的治疗策略、监测活动和药物开发平臺。本执行摘要整合了当前该领域的交叉趋势、技术转折点、监管压力和运营挑战，旨在为检查室、医疗保健系统、药物研发和公共卫生领域的领导者提供简洁明了、基于证据的概述，帮助他们调整自身能力以满足不断变化的临床和商业性需求。

自动化、分子诊断、劳动力短缺和整合服务如何重塑检查室领域的实验室工作流程和供应商关係。

近年来，支撑诊断技术、检查室操作和合理使用抗生素的整个生态系统都发生了变革性变化。自动化技术已从独立的分析仪器发展成为集自动化​​系统、盘式分析仪和互联资料管道于一体的完全整合平台。这种转变不仅减少了人工劳动，还提高了可重复性和资料完整性，使大规模机构能够在保证品质的前提下扩大检测能力。同时，基因分型和分子检测技术的进步提供了对传统表型检测的补充讯息，加速了抗药性决定因素的识别，并指南了精准医疗的发展。

我们将评估贸易政策对诊断设备采购、试剂持续供应以及在不断变化的关税环境下筹集资金等方面的选择所产生的累积影响。

政策变化，例如关税和跨境贸易成本的调整，会对诊断供应链和筹资策略产生连锁反应，进而影响设备供应、试剂供应和价格走势。进口诊断组件和成品设备的关税上涨将导致检查室和製造商面临更高的接收成本，通常需要重新评估供应商合约和库存策略。有些机构会加快在拥有合格供应商的地区进行在地采购，而有些机构则会协商长期供应合约以规避贸易波动风险。此外，关税上涨可能会影响资本投资决策的步伐，促使买家延长设备使用寿命或优先考虑模组化升级而非平台更换。

透过整合产品、测试、方法、应用和最终用户观点进行細項分析，可以揭示创新和商业化的优先目标。

了解产品、测试、方法、应用和最终用户等细分领域之间的交集，对于协调研发重点、筹资策略和商业化计划至关重要。依产品类型划分，市场涵盖仪器、试剂盒和服务。仪器包括自动化系统和手动仪器，其中自动化系统又细分为自动分析仪和自动盘式分析仪。试剂盒分为抗生素敏感性测试试剂盒和微生物鑑定试剂盒，而服务则涵盖分析测试服务和客製化测试解决方案。这种产品层面的区分凸显了自动化投资与试剂组合或外包服务投资相比，对耗材消耗、供应商锁定和工作流程重新设计的影响各不相同。

美洲、欧洲、中东和非洲以及亚太地区诊断技术和供应链策略的采用情况，为制定适合各地区的商业性方法提供了重要的见解。

区域趋势塑造着需求模式和供应链策略，因此，在全球规划中，了解这些细微的区域差异至关重要。在美洲，需求主要大规模医院网路、先进的临床检查室以及对合理使用抗生素的高度重视所驱动，而这又与支付方和监管机构的期望密切相关，进而推动了自动化和互联诊断平台的普及。供应链的韧性始终是人们关注的焦点，这促使企业制定本地库存策略，并建立长期的供应商关係，以确保试剂和耗材的稳定供应。在欧洲、中东和非洲，监管的多样性和资源的差异导致了不同的应用普及率。虽然欧洲市场的一些领先实验室优先考虑先进的分子诊断和自动化表型分析工作流程，但该地区的其他一些实验室则更注重成本效益高且稳健的方法，这些方法即使在基础设施有限的环境中也能大规模部署。

设备供应商、试剂专家和服务供应商之间的竞争与合作策略正在塑造平台整合和经常性收入模式。

竞争格局由成熟的诊断设备製造商、专业试剂供应商以及提供分析检测和客製化解决方案的服务供应商组成。现有设备供应商持续投资于平台整合、软体驱动的决策支援和互通性，以维持其在临床检测领域的地位。同时，小规模、更灵活的公司正在开发针对特定抗药性机制的基因分型检测和专用试剂组，这为与寻求拓展检测业务的大型公司建立合作关係创造了机会。服务供应商透过提供端到端的验证支援、远端设备监控以及旨在满足监管申报要求的客製化检测方案来脱颖而出。

为经营团队提供切实可行的建议，以增强韧性、加快自动化采用，并建立符合使用者需求的差异化产品和服务结构。

领导者必须采取积极主动的措施来抓住机会并降低风险。首先，应优先投资于自动化和可互通的软体，以减少人工工作量、提高可重复性，并实现临床和研究环境中的可扩展测试。其次，应实现供应链多元化，认证关键试剂和耗材的替代供应商，并建立合约机制，即使在供应中断期间也能灵活承诺数量并优先供应。此外，还应加强诊断开发人员和最终用户之间的合​​作，共同设计检验研究和服务模式，以应对实际检查室中的各种限制和监管要求。

为确保实际相关性和方法论的严谨性，采用了稳健的混合方法研究方法，结合了初次访谈、技术检验和第二手资料。

本调查方法采用多层次调查方法，整合了初步访谈、对二手资讯的严格检验以及技术检验练习。初步数据透过实验室经理、采购经理、诊断试剂开发人员和服务供应商的结构化访谈收集，以了解营运重点、采购因素和创新蓝图。二手研究整合了同行评审文献、监管指南和技术白皮书，以检验定性和定量检测方法之间的差异，并了解自动化分析仪、自动盘式分析仪和分子检测技术的性能标准演变。

为实现先进药敏试验的临床和公共卫生效益，对技术、营运和商业性策略进行总结。

抗菌药物敏感性检测正处于转折点，技术创新、营运压力和政策趋势的融合正在重塑诊断实践。自动化、互补基因分型方法和数据驱动的合理应用工具的持续进步有望提高诊断速度和临床决策水平，同时也对检验、互通性和人力资源能力提出了新的要求。供应链的韧性和灵活的商业模式预计将影响检查室和研究机构采用新平台和检测方法的速度。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗菌药物敏感性测试市场：依产品类型划分

  • 装置
    • 自动化系统
      • 自动分析仪
      • 自动盘式分析仪
    • 手动设备
  • 试剂和试剂盒
    • 抗菌药物敏感性测试试剂盒
    • 微生物鑑定试剂盒
  • 服务
    • 分析测试服务
    • 客製化检测解决方案

第九章：按检测类型分類的抗菌药物敏感性检测市场

  • 抗菌药物敏感性试验
  • 抗真菌药物敏感性试验
  • 抗寄生虫药物敏感性试验
  • 抗病毒药物敏感性试验

第十章：抗菌药物敏感性测试市场：依方法划分

  • 定性方法
    • 琼脂稀释法
    • 自动AST
    • 纸锭扩散法
    • 基因分型
  • 定量方法
    • 肉汤大稀释法
    • Etest 方法

第十一章：抗菌药物敏感性测试市场：按应用领域划分

  • 临床诊断
  • 药物发现与开发
  • 流行病学

第十二章：抗菌药物敏感性测试市场：依最终用户划分

  • 学术和政府附属研究机构
  • 医院和诊断中心
  • 製药和生物技术公司

第十三章：抗菌药物敏感性检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：抗菌药物敏感性测试市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 抗菌药物敏感性检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗菌药物敏感性检测市场

第十七章：中国抗菌药物敏感性检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Alifax Srl
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • Biological Safety Solutions Ltd/Oy
  • BioMerieux SA
  • Bruker Corporation
  • Creative Diagnostics
  • Danaher Corporation
  • Erba Lachema sro
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Himedia Laboratories Private Limited
  • INTEGRA Biosciences AG
  • Laboratorios Conda, SA
  • Launch Diagnostics Limited
  • Leading Biology, Inc.
  • Liofilchem Srl
  • Mast Group Ltd.
  • MP Biomedicals, LLC
  • Pfizer Inc.
  • Qiagen NV
  • QuantaMatrix Inc.
  • Resistell AG
  • Synoptics Group
  • Thermo Fisher Scientific Inc.
  • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-464C422F4BD3

The Antimicrobial Susceptibility Testing Market was valued at USD 4.25 billion in 2025 and is projected to grow to USD 4.50 billion in 2026, with a CAGR of 6.07%, reaching USD 6.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.25 billion
Estimated Year [2026] USD 4.50 billion
Forecast Year [2032] USD 6.43 billion
CAGR (%) 6.07%

A concise strategic introduction framing antimicrobial susceptibility testing trends, operational imperatives, and diagnostic innovation that guide clinical and R&D decision-making

Antimicrobial susceptibility testing is a cornerstone of clinical microbiology and therapeutic stewardship, influencing treatment decisions, surveillance activities, and drug development pipelines worldwide. This executive summary synthesizes cross-cutting trends, technological inflection points, regulatory pressures, and operational imperatives shaping the field today. It aims to provide a concise, evidence-based briefing for leaders in laboratories, health systems, pharmaceutical development, and public health who must align capabilities with evolving clinical and commercial demands.

The landscape is defined by the convergence of automation, molecular diagnostics, and data-driven decision support. Faster time-to-result and improved reproducibility are driving investment in automated instruments and integrated workflows, while genotypic approaches complement phenotypic assays to give clinicians a richer understanding of resistance mechanisms. At the same time, regulatory scrutiny of diagnostic performance, reimbursement dynamics, and supply chain resiliency continue to affect implementation timelines and capital allocation. This introduction frames the topics addressed in the following sections and sets expectations for actionable insights that follow, positioning readers to evaluate strategic options in procurement, laboratory modernization, and collaborative research.

How automation, molecular diagnostics, workforce constraints, and integrated services are reshaping laboratory workflows and supplier relationships in diagnostics

Recent years have ushered in transformative shifts across diagnostic technology, laboratory operations, and the broader ecosystem that supports antimicrobial stewardship. Automation has moved beyond stand-alone analyzers toward fully integrated platforms that combine automated systems, plate readers, and connected data pipelines. This change not only reduces hands-on time but also elevates reproducibility and data integrity, enabling larger institutions to scale testing capacity while maintaining quality. Simultaneously, advances in genotypic methods and molecular panels are providing complementary insights to traditional phenotypic assays, accelerating identification of resistance determinants and informing precision therapy.

Workforce dynamics and laboratory consolidation are forcing organizations to rethink workflows; shortages of skilled technicians increase the value of automation and remote monitoring capabilities. Reagents and kits are evolving too, with manufacturers optimizing formulations for stability and compatibility with automated analyzers and automated plate readers to reduce variability and logistical burden. Services are expanding beyond routine analytical testing to offer custom testing solutions and advisory support for assay validation and regulatory submissions. Taken together, these forces are reshaping procurement priorities, vendor relationships, and the structure of diagnostic service offerings, prompting stakeholders to prioritize agile, interoperable solutions that support both clinical diagnostics and drug development pathways.

Evaluating cumulative trade policy impacts on diagnostic sourcing, reagent continuity, and capital procurement choices amid changing tariff environments

Policy shifts that alter duties and cross-border trade costs can ripple through diagnostic supply chains and procurement strategies, influencing instrument sourcing, reagent availability, and pricing dynamics. When tariffs increase on imported diagnostic components or finished instruments, laboratories and manufacturers face higher landed costs that often require re-evaluation of supplier contracts and inventory strategies. Some organizations respond by accelerating local sourcing where capable suppliers exist, while others negotiate long-term supply agreements to hedge exposure to trade volatility. In addition, higher tariffs can affect the cadence of capital investment decisions, prompting buyers to extend equipment lifecycles or prioritize modular upgrades over full platform replacements.

Beyond direct cost effects, tariff changes can create secondary impacts on innovation diffusion and service delivery. Manufacturers with geographically diversified production footprints may reallocate manufacturing to regions with preferential trade terms, which can alter lead times and qualification requirements for regulatory filings. Service providers that perform analytical testing and custom testing solutions may need to adjust pricing or revise cross-border service agreements to maintain margins. For clinical entities and research organizations, the pragmatic response often combines inventory buffering, supplier diversification, and closer collaboration with vendors to secure continuity of reagents and critical consumables. Ultimately, the cumulative effects of tariff shifts emphasize the importance of resilient sourcing strategies, contractual flexibility, and scenario planning to manage supply chain risk while sustaining diagnostic quality and operational continuity.

Integrated segmentation analysis that aligns product, test, method, application, and end-user perspectives to reveal priority targets for innovation and commercialization

Understanding how product, test, method, application, and end-user segments intersect is essential to aligning R&D priorities, procurement strategies, and commercialization plans. Based on product type, the landscape spans instruments, reagents and kits, and services; instruments include automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers; reagents and kits divide into antibiotic susceptibility kits and microbial identification kits; and services encompass analytical testing services and custom testing solutions. This product-level distinction underscores that investments in automation will carry different implications for consumable consumption, vendor lock-in, and workflow redesign than investments in reagent portfolios or outsourced services.

Test type segmentation reflects clinical and research needs across antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and antiviral susceptibility testing, each with distinct methodological requirements and clinical urgency. Method segmentation separates qualitative and quantitative approaches; qualitative methods include agar dilution, automated AST, disk diffusion, and genotypic methods, while quantitative methods comprise broth macrodilution and the Etest method. These methodological differences influence laboratory throughput, interpretive complexity, and regulatory validation pathways. Application segmentation shows demand centers in clinical diagnostics, drug discovery and development, and epidemiology, which in turn shape acceptance criteria and data deliverables. Finally, end-user segmentation identifies academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies as primary consumers, each with unique procurement cycles, performance expectations, and budgetary constraints. Combining these lenses reveals where innovation will be most valuable, which channels require targeted commercial strategies, and how validation and service models should be configured to meet user needs.

Regional diagnostic adoption and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform tailored commercial approaches

Regional dynamics shape both demand patterns and supply chain strategies, and a nuanced view across geographies is critical for global planning. In the Americas, demand is driven by large hospital networks, advanced clinical laboratories, and a strong emphasis on antimicrobial stewardship tied to payer and regulatory expectations, which favors adoption of automation and connected diagnostic platforms. Supply chain resilience is a recurring concern, motivating local inventory strategies and longer-term supplier relationships to ensure steady access to reagents and consumables. Across Europe, Middle East & Africa, regulatory heterogeneity and resource variability create differentiated adoption trajectories; leading laboratories in some European markets prioritize advanced molecular and automated phenotypic workflows, while parts of the broader region focus on cost-effective, robust methods that can be deployed at scale with constrained infrastructure.

Asia-Pacific presents a mixed picture of rapid capacity expansion, significant public health-driven surveillance programs, and growing domestic manufacturing capabilities for reagents and instruments. Investment in laboratory infrastructure and public health surveillance is increasing in many markets, bolstering demand for both automated systems and analytical testing services. These regional contrasts mean that product design, commercial models, and partnership strategies must be tailored; solutions that succeed in one geography may need adaptation in pricing, service delivery, and regulatory support to achieve traction elsewhere. Cross-border collaboration and strategic regional partnerships can help bridge capability gaps, accelerate technology transfer, and align supply networks with regional priorities.

Competitive dynamics and partnership strategies among instrument vendors, reagent specialists, and service providers shaping platform integration and recurring revenue models

The competitive landscape is being shaped by a mix of established diagnostic manufacturers, specialized reagent suppliers, and service providers offering analytical testing and custom solutions. Incumbent instrument vendors continue to invest in platform integration, software-enabled decision support, and interoperability to maintain clinical laboratory relevance. At the same time, smaller and more agile firms are advancing genotypic assays and niche reagent kits that address specific resistance mechanisms, enabling partnership opportunities with larger firms seeking to broaden their test menus. Service providers are differentiating by offering end-to-end validation support, remote instrument monitoring, and customized testing panels designed to meet regulatory submission needs.

Strategic behavior includes forming alliances to accelerate market entry, pursuing acquisitions to fill portfolio gaps, and expanding service capabilities to capture recurring revenue from consumables and testing contracts. Manufacturers are also investing in digital tools that aggregate susceptibility data for local surveillance and stewardship programs, creating stickiness and value beyond the instrument sale. For pharmaceutical and biotechnology companies, collaborations with diagnostic developers and contract service providers are increasingly important to de-risk antimicrobial drug development through integrated testing strategies. Overall, competitive advantage accrues to organizations that combine technical excellence with adaptable commercial models, robust supply chains, and strong customer support frameworks.

Actionable recommendations for executives to strengthen resilience, accelerate automation adoption, and build differentiated product and service offerings aligned with user needs

Leaders must act deliberately to capture opportunities and mitigate risk. First, prioritize investments in automation and interoperable software that reduce manual workload, improve reproducibility, and enable scalable testing across clinical and research settings. Next, diversify supply chains and qualify alternate suppliers for key reagents and consumables, and establish contractual mechanisms that allow flexible volume commitments and priority fulfillment during supply disruptions. Strengthen collaboration between diagnostic developers and end users by co-designing validation studies and service models that address real-world laboratory constraints and regulatory expectations.

Additionally, invest in workforce development to close skill gaps through targeted training programs, remote monitoring tools, and workflow redesign that optimize the use of scarce specialist talent. For companies commercializing tests or instruments, adopt flexible pricing and service bundles that reflect the needs of distinct end users such as academic research centers, hospital systems, and pharmaceutical development teams. Finally, integrate surveillance data products and stewardship support into offerings to create differentiated value, foster long-term customer relationships, and demonstrate public health impact. These steps create a pragmatic roadmap to balance short-term resilience with long-term growth and innovation.

Robust mixed-methods research approach combining primary interviews, technical validation, and secondary evidence to ensure practical relevance and methodological rigor

The research approach combines a layered methodology that integrates primary interviews, rigorous secondary source triangulation, and technical validation exercises. Primary data was collected through structured interviews with laboratory directors, procurement leads, diagnostic developers, and service providers to capture operational priorities, procurement drivers, and innovation roadmaps. Secondary research synthesized peer-reviewed literature, regulatory guidance, and technical white papers to validate methodological distinctions across qualitative and quantitative testing approaches and to understand evolving performance standards for automated analyzers, automated plate readers, and molecular assays.

Technical validation involved cross-referencing method characteristics-such as throughput, time-to-result, and interpretive complexity-against documented laboratory workflows and published performance evaluations for genotypic and phenotypic methods. Supply chain and policy analyses incorporated trade data and public procurement patterns to assess vulnerability points and potential mitigation strategies. Throughout, findings were iteratively reviewed with subject matter experts to ensure accuracy and practical relevance. This mixed-methods design ensures that conclusions are grounded in real-world practice while reflecting the technical nuances of assay development, instrument integration, and service delivery.

Concluding perspective on aligning technological, operational, and commercial strategies to realize the clinical and public health benefits of advanced susceptibility testing

Antimicrobial susceptibility testing is at an inflection point where technological innovation, operational pressures, and policy dynamics converge to reshape diagnostic practice. The continued push toward automation, complementary genotypic methods, and data-enabled stewardship tools promises to improve diagnostic speed and clinical decision-making, while also introducing new requirements for validation, interoperability, and workforce competencies. Supply chain resilience and adaptable commercial models will influence how quickly laboratories and research organizations can adopt new platforms and assays.

Stakeholders that align investment with clear use-case prioritization-distinguishing the needs of clinical diagnostics, drug discovery and development, and epidemiology-will capture the greatest value. By integrating product-level strategies, regional tailoring, and partnerships that bridge technical and commercial gaps, organizations can both mitigate near-term risks and position themselves for sustained impact. The path forward favors pragmatic innovation that is interoperable, validated in real-world settings, and supported by service models that address the full lifecycle of instruments, reagents, and testing programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Susceptibility Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Systems
      • 8.1.1.1. Automated Analyzers
      • 8.1.1.2. Automated Plate Readers
    • 8.1.2. Manual Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Antibiotic Susceptibility Kits
    • 8.2.2. Microbial Identification Kits
  • 8.3. Services
    • 8.3.1. Analytical Testing Services
    • 8.3.2. Custom Testing Solutions

9. Antimicrobial Susceptibility Testing Market, by Test Type

  • 9.1. Antibacterial Susceptibility Testing
  • 9.2. Antifungal Susceptibility Testing
  • 9.3. Antiparasitic Susceptibility Testing
  • 9.4. Antiviral Susceptibility Testing

10. Antimicrobial Susceptibility Testing Market, by Method

  • 10.1. Qualitative Methods
    • 10.1.1. Agar Dilution
    • 10.1.2. Automated Ast
    • 10.1.3. Disk Diffusion
    • 10.1.4. Genotypic Method
  • 10.2. Quantitative Methods
    • 10.2.1. Broth Macrodilution
    • 10.2.2. Etest Method

11. Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery & Development
  • 11.3. Epidemiology

12. Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Academic & Government Research Institutes
  • 12.2. Hospitals & Diagnostic Centers
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Antimicrobial Susceptibility Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimicrobial Susceptibility Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimicrobial Susceptibility Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antimicrobial Susceptibility Testing Market

17. China Antimicrobial Susceptibility Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Accelerate Diagnostics, Inc.
  • 18.6. Alifax S.r.l.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
  • 18.10. Biological Safety Solutions Ltd/Oy
  • 18.11. BioMerieux SA
  • 18.12. Bruker Corporation
  • 18.13. Creative Diagnostics
  • 18.14. Danaher Corporation
  • 18.15. Erba Lachema s.r.o.
  • 18.16. Eurofins Scientific SE
  • 18.17. F. Hoffmann-La Roche AG
  • 18.18. Himedia Laboratories Private Limited
  • 18.19. INTEGRA Biosciences AG
  • 18.20. Laboratorios Conda, S.A.
  • 18.21. Launch Diagnostics Limited
  • 18.22. Leading Biology, Inc.
  • 18.23. Liofilchem S.r.l.
  • 18.24. Mast Group Ltd.
  • 18.25. MP Biomedicals, LLC
  • 18.26. Pfizer Inc.
  • 18.27. Qiagen N.V.
  • 18.28. QuantaMatrix Inc.
  • 18.29. Resistell AG
  • 18.30. Synoptics Group
  • 18.31. Thermo Fisher Scientific Inc.
  • 18.32. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES A